Obesity Strategic Roundup: Beyond GLP-1 Efficacy | Sep 1 – Oct 4 , 2026
How are next-generation obesity therapies reshaping competition in the GLP-1…
Nanexa–Novo Nordisk PharmaShell Deal: From Validation to Development | Lucid Diligence Brief
This Lucid Diligence Brief examines the Nanexa–Novo Nordisk PharmaShell deal…
Obesity Strategic Roundup | Jul 28 – Aug 31 , 2026
Obesity Strategic Roundup exploring Developments and Competitive Shifts…
Vida Health and Instacart Health Partner on Fresh Funds | Lucid Diligence Brief
Vida Health’s Instacart Health partnership tests whether grocery stipends can…
Public Health Today—April 24, 2026
This weekly Public Health update highlights key developments across policy,…
Obesity Today—April 7, 2026
This week’s Obesity update highlights regulatory progress, advancing late-stage…
Lucid Diligence Brief: Ambrosia Biosciences $100M Series B for oral GLP-1 asset
Lucid Diligence Brief: Ambrosia Biosciences $100M Series B for oral GLP-1……
Lucid Diligence Brief: Samsung Bioepis and G2GBIO long-acting semaglutide collaboration
Lucid Diligence Brief: Samsung Bioepis and G2GBIO long-acting semaglutide…
Lucid Diligence Brief: Hims & Hers to acquire Eucalyptus
Lucid Diligence Brief: Hims & Hers to acquire Eucalyptus Professional…
Lucid Diligence Brief: AstraZeneca and CSPC obesity and T2D collaboration
Lucid Diligence Brief: AstraZeneca and CSPC obesity and T2D collaboration…
Lucid Diligence Brief: CORXEL $287m Series D1 for oral GLP-1 development
Lucid Diligence Brief: CORXEL $287m Series D1 for oral GLP-1 development…
Obesity Video Recap—January 20, 2026
This biweekly Obesity video recap covers a mix of late-stage regulatory…